Skip to Content
Merck
All Photos(2)

Documents

SBR00036

Sigma-Aldrich

Rhodamine B labeled Polymyxin B Ready Made Solution

For fluorescent microbial imaging, 1.1 mg/mL in water

Synonym(s):

SRB-PMB

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
12352211
NACRES:
NA.47

Quality Level

100

concentration

1.1 mg/mL in water

lipid type

saturated FAs

storage temp.

−20°C

General description

Rhodamine B labeled polymyxin B (SRB-PMB) is a fluorescent derivative of Polymyxin B. Rhodamine B polymyxin B is an additional fluorescent derivative of Polymyxin B, along with Dansyl labeled polymyxin B (Product # SBR00029). Both products′ mode of action is in accordance with Polymyxin B activity. Fluorescent antibiotics are obtained by synthetic conjugation of an antibiotic to a fluorophore.

Application

Fluorescent antibiotics can be used for many applications including:
  • Antimicrobial resistance research.
  • Bacterial visualization and imaging.
  • Parent antibiotic mode of action research and new antibiotic discovery.
  • Toxicity studies.
  • Research of bacterial infections and tracking its uptake in vivo.

Additional possible applications for Rhodamine B labeled Polymyxin B:
  • Evaluate LPS binding by FRET (fluorescence resonance energy transfer) studies to form a specific complex between fluorescein (FITC)-tagged LPS and Polymyxin B, indicating direct binding of the antibiotic to the LPS
  • Can be applied as a fluorescent probe to study polymyxin mode of action and its pharmacokinetics
  • to assess the mitochondrial function of polymyxin B in a kidney cell line (LLC-PK1), suggesting that it changes the mitochondrial membrane polarization.

Analysis Note

  • Rhodamine B labeled polymyxin B Ready Made Solution is light sensitive.
  • It is recommended to avoid freeze-thaw cycles of Rhodamine B labeled polymyxin B Ready-Made Solution
  • Rhodamine B labeled polymyxin B Ready Made Solution (1.1mg/mL) can be diluted 1:100-200 in PBSX1 (Product# D8537) to achieve 0.55-1.1μg/mL final concentration for staining. The above concentration of Rhodamine B labeled polymyxin B was used for Escherichia coli staining (see image)
  • Fluorescence Microscopy application: Rhodamine B labeled polymyxin B Ready Made Solution excitation (Ex) wavelength is 550-560nm resulting in emission (Em) range of 580-610nm (λmax=590-600nm)

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

P R Schindler et al.
Antimicrobial agents and chemotherapy, 8(1), 95-104 (1975-07-01)
Though the primary action of the cationic antibiotic polymyxin B is against the membrane of susceptible bacteria, severe morphological changes are detected in the cytoplasm. Using fluorescence microscopy and a mono-N-dansyl-polymyxin B derivative, we could demonstrate aggregations of the antibiotic
Kinetics and Mechanism of the Recognition of Endotoxin by Polymyxin B
Thomas C J, et al.
Journal of the American Chemical Society, 120(48), 12428-12434 (1998)
R E Hancock
Lancet (London, England), 349(9049), 418-422 (1997-02-08)
The era of the "classical antibiotic" may be over. The emergence of resistance has seen to that. Yet no truly novel class of antibacterial agent has come on the market in the past 30 years. Currently there is great interest
Vincent H Tam et al.
Antimicrobial agents and chemotherapy, 49(9), 3624-3630 (2005-08-30)
Despite limited data, polymyxin B (PB) is increasingly used clinically as the last therapeutic option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in vitro pharmacodynamics of PB against four strains of Pseudomonas aeruginosa. Clonal relatedness of the strains
Zakuan Z Deris et al.
Bioconjugate chemistry, 25(4), 750-760 (2014-03-19)
The dry antibiotic development pipeline coupled with the emergence of multidrug resistant Gram-negative 'superbugs' has driven the revival of the polymyxin lipopeptide antibiotics. Polymyxin resistance implies a total lack of antibiotics for the treatment of life-threatening infections. The lack of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service